Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
While the branded versions are FDA-approved for specific uses, compounded versions are prepared based on individual prescriptions and are often used during periods of medication shortages
Unlike traditional GLP-1 receptor agonists, Retatrutide is a triple hormone receptor agonist, targeting: GLP-1 GIP Glucagon This unique mechanism has shown promising results in clinical trials, including: Significant weight loss Improved glycemic control in people with type 2 diabetes Better insulin sensitivity Potential improvements in cardiometabolic health and liver fat Once-weekly administration in clinical studies Its important to remember that Retatrutide is still an investigational medication and has not yet received regulatory approval for routine clinical use in many countries
Studies on GLP-1 medications show that approximately 25-40% of weight lost can come from lean mass rather than fat mass
If degradation has reduced the potency by 20%, your 2.5mg dose is actually delivering 2mg
Regulatory uncertainty shadows the compounded GLP-1 market
